NCT04890353 is a Phase 1, PHASE2 clinical trial of Dimethyl fumarate in Acute Ischemic Stroke, sponsored by Xuanwu Hospital, Beijing.

Who is sponsoring NCT04890353?

NCT04890353 is sponsored by Xuanwu Hospital, Beijing.

What drugs are being tested in NCT04890353?

Interventions in NCT04890353: Dimethyl fumarate.

What condition does NCT04890353 study?

NCT04890353 studies Acute Ischemic Stroke.

Is NCT04890353 still recruiting?

NCT04890353 is currently terminated. Last updated 25 October 2023.

Last reviewed 2023-10-25 · How we verify

NCT04890353

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke

Terminated Phase 1, PHASE2 Last updated 25 October 2023

What this trial tests

Phase 1, PHASE2 trial testing Dimethyl fumarate in Acute Ischemic Stroke in 2 participants. Terminated before completion.

Timeline

1 December 2021

Primary endpoint
8 February 2023

28 February 2023

Quick facts

Lead sponsor	Xuanwu Hospital, Beijing
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	2
Start date	1 December 2021
Primary completion	8 February 2023
Estimated completion	28 February 2023
Sites	1 location across China

Drugs / interventions tested

Dimethyl fumarate (DIMETHYL FUMARATE) — full drug profile →

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →

Sponsor

Xuanwu Hospital, Beijing

Who can join

18 and older, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in in alleviating neurologic deficits in patients with Acute Ischemic Stroke.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders.
Tastan B, Arioz BI, Genc S. · · 2022 · cited 56× · PMID 35418995 · DOI 10.3389/fimmu.2022.865772
Neuroinflammation and anti-inflammatory therapy for ischemic stroke.
Cao Y, Yue X, Jia M, Wang J. · · 2023 · cited 35× · PMID 37519706 · DOI 10.1016/j.heliyon.2023.e17986
Repurposing Dimethyl Fumarate for Cardiovascular Diseases: Pharmacological Effects, Molecular Mechanisms, and Therapeutic Promise.
Thomas SD, Jha NK, Sadek B, Ojha S. · · 2022 · cited 15× · PMID 35631325 · DOI 10.3390/ph15050497
The Challenge of Dimethyl Fumarate Repurposing in Eye Pathologies.
Manai F, Govoni S, Amadio M. · · 2022 · cited 11× · PMID 36552824 · DOI 10.3390/cells11244061
Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.
Cuadrado A, Cazalla E, Bach A, Bathish B, et al · · 2025 · cited 9× · PMID 40059038 · DOI 10.1016/j.redox.2025.103569
Dimethyl fumarate as a versatile therapeutic agent: molecular mechanisms and potential clinical applications.
Zingkou E, Medoro A, Davinelli S, Saso L, et al · · 2026 · cited 1× · PMID 41627610 · DOI 10.1007/s11033-026-11478-7
Programmed cell death inhibitors: a new hope for cancer therapy?
Zhong Y, Zhang Y, Cheng L, Chen Q, et al · · 2026 · PMID 41664148 · DOI 10.1186/s12957-026-04241-6

Verify or expand the search:

Other trials of Dimethyl fumarate

Trials testing the same drug.

NCT06513533 — Dimethyl Fumarate in Adrenomyeloneuropathy · Phase 2, PHASE3 · recruiting
NCT05959759 — Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms. · Phase 4 · unknown
NCT05658484 — A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China · Phase 4 · completed
NCT04890379 — Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage · Phase 2 · withdrawn
NCT04756687 — Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera · completed

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other Xuanwu Hospital, Beijing trials

Trials by the same sponsor.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04890353 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
Last refreshed: 25 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04890353.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing